Porous silicon drug-eluting particles

• US 9,962,396 B2
• Filed: 11/07/2016
• Issued: 05/08/2018
• Est. Priority Date: 05/04/2009
• Status: Active Grant

• Current Assignee: EyePoint Pharmaceuticals, Inc.
• Original Assignee: pSivida US, Inc
• Inventors: Ashton, Paul, Guo, Hong, Chen, Jianbing, Canham, Leigh T.
• Primary Examiner(s): Pallay, Michael B.
• Application Number:
  US15/330,836
• Publication Number:
  US 20170128464A1
• Time in Patent Office: 547 Days
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/0097 Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips intradermal microneedle arrays A61K9/0021; MEMS in general B81B7/02
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention. The invention also provides methods of fabricating a drug-eluting particle for releasing therapeutic agents.

Claims

1. A biodegradable drug-eluting particle comprising:

a porous silica body;

a reservoir formed within the porous silica body having at least one opening to an exterior of the body, wherein the reservoir has a diameter of at least about 120 μ

m;

a drug core within the reservoir wherein the drug core comprises a therapeutic or diagnostic agent; and

an agent-permeable seal disposed over the at least one opening.

2. The particle of claim 1, wherein the particle has at least two openings to an exterior of the body and an agent-permeable seal disposed over the at least two openings.

3. The particle of claim 2, wherein the particle has a plurality of openings to an exterior of the body and one or more agent-permeable seals covering each of the plurality of openings.

4. The particle of claim 1, wherein the particle has at least one dimension less than 1 mm.

5. The particle of claim 1, wherein the porous silica body is mesoporous.

6. The particle of claim 1, wherein the drug core comprises 0.01 to 50 mg of the agent.

7. The particle of claim 1, wherein the drug core comprises from 0.05 to 20 mg of the agent.

8. The particle of claim 1, wherein the drug core comprises a therapeutic agent.

9. The particle of claim 8, wherein the therapeutic agent is for treating or preventing an ocular condition.

10. The particle of claim 9, wherein the therapeutic agent is fluocinolone acetonide.

11. The particle of claim 1, wherein the drug core comprises a diagnostic agent.

12. The particle of claim 11, wherein the diagnostic agent is for ophthalmic use.

13. The particle of claim 1, wherein the particle is partially biodegradable in a patient.

14. A method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering the biodegradable drug-eluting particle of claim 1 to a patient and allowing the agent to elute from the particle and come in direct contact with cells or tissues of the patient.